POLYMED

At Polymed we focus on novel therapies in the areas of oncology and auto-immune diseases. We aim at creating first-in-class and best-in-class medicines for treating patients using advanced technology platforms including artificial intelligence and structural biology. The approaches we use includes traditional protein inhibition and modern protein degradation. The aim is to deliver drugs for "undruggable" targets.... Chemical binding compounds can effectively inhibit the function of target proteins that possess "ideal binding pockets". This type of targets accounts only less than 20% of possible disease targets, with the remaining 80% called "undruggable targets". To hit these "undruggable targets" new methods and novel modalities have been developed. Among these are target degradation methods and covalent bonding modalities. At Polymed we deploy these new approaches for cancer and other disease targets.

Primary location: Hangzhou China